Journal
JOURNAL OF CLINICAL LABORATORY ANALYSIS
Volume 36, Issue 7, Pages -Publisher
WILEY
DOI: 10.1002/jcla.24517
Keywords
CD9; neoadjuvant chemotherapy; pancreatic cancer; prognostic factor
Categories
Funding
- National Science Foundation for Distinguished Young Scholars of China [81625016]
- National Natural Science Foundation of China [81,871,941, 81,872,366, 81,827,807, 81,802,675, 81,701,630, 81,702,341]
- National Key R&D Program of China [2019YFC1315900]
- Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]
- Natural Science Foundation of Shanghai [19ZR1410800]
- Clinical and Scientific Innovation Project of Shanghai Hospital Development Center [SHDC12018109]
- Clinical Research Plan of Shanghai Hospital Development Center [SHDC2020CR1006A]
Ask authors/readers for more resources
The expression of CD9 in pancreatic cancer patients is significantly correlated with clinical and pathological features. In the neoadjuvant group, high levels of tumor CD9 expression are associated with poorer survival, while high levels of stromal CD9 expression are associated with better survival. CD9 has an independent prognostic impact in pancreatic cancer patients.
Background The selective pressure imposed by chemotherapy creates a barrier to tumor eradication and an opportunity for metastasis and recurrence. As a newly discovered stemness marker of pancreatic ductal adenocarcinoma (PDAC), the impact of CD9 on tumor progression and patient's prognosis remain controversial. Methods A total of 179 and 211 PDAC patients who underwent surgical resection with or without neoadjuvant chemotherapy, respectively, were recruited for immunohistochemical analyses of CD9 expression in both tumor and stromal areas prior to statistical analyses to determine the prognostic impact and predictive accuracy of CD9. Results The relationship between CD9 and prognostic indicators was not significant in the non-neoadjuvant group. Nevertheless, CD9 expression in both tumor (T-CD9) and stromal areas (S-CD9) was significantly correlated with the clinicopathological features in the neoadjuvant group. High levels of T-CD9 were significantly associated with worse OS (p = 0.005) and RFS (p = 0.007), while positive S-CD9 showed the opposite results (OS: p = 0.024; RFS: p = 0.008). Cox regression analyses identified CD9 in both areas as an independent prognostic factor. The T&S-CD9 risk-level system was used to stratify patients with different survival levels. The combination of T&S-CD9 risk level and TNM stage were accurate predictors of OS (C-index: 0.676; AIC: 512.51) and RFS (C-index: 0.680; AIC: 519.53). The calibration curve of the nomogram composed of the combined parameters showed excellent predictive consistency for 1-year RFS. These results were verified using a validation cohort. Conclusion Neoadjuvant chemotherapy endows CD9 with a significant prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available